Bristol Myers Squibb elects former Agilent CEO Michael McMullen to board

BRISTOL MYERS SQUIBB CO

Michael R. McMullen elected to board, effective July 1, 2024; board size increases to 11.
McMullen served as Agilent CEO 2015-2024, nearly tripled market cap; independent director.
He will serve on Audit Committee; receives $110k annual retainer + $210k in deferred share units.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael R. McMullen

Director

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2024-07-01
Filed: June 18, 2024, 7:59 PM ET

On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael R. McMullen was elected as Director at BRISTOL MYERS SQUIBB CO.

Action: elected
Role: Director

Exact text from the filing

On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.

View on SEC.gov

BRISTOL MYERS SQUIBB CO filing history →

Source: SEC EDGAR

accession 0001140361-24-030533

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.